Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer

By Moreno-Aspitia Alvaro   Perez Edith A  

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 755-762

Future Medicine

Access to resources Recommend Favorite

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer

By                

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1822-1826

Spandidos Publications

Access to resources Recommend Favorite

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

By Yardley Denise   Burris Howard   Peacock Nancy   Raefsky Eric   Melnik Marianne   Inhorn Roger   Shipley Dianna   Hainsworth John  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 471-475

Springer Publishing Company

Access to resources Recommend Favorite

Safety of nanoparticle albuminbound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports

By                    

Oncology Letters, Vol. 6, Iss. 4, 2013-01 ,pp. : 881-884

Spandidos Publications

Access to resources Recommend Favorite

Short-term outcomes of albumin-bound paclitaxel (abraxane)-containing chemotherapy in patients with advanced gastric cancer: a report of 14 cases

By Yan Zheng   Xia Liangping   Qiu Huijuan   Chen Ping   Zhang Bei  

The Chinese-German Journal of Clinical Oncology, Vol. 12, Iss. 1, 2013-01 ,pp. : 30-34

Springer Publishing Company

Access to resources Recommend Favorite